(NASDAQ: MIRM) Mirum Pharmaceuticals's forecast annual revenue growth rate of 19.79% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.17%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.45%.
Mirum Pharmaceuticals's revenue in 2026 is $618,067,000.On average, 14 Wall Street analysts forecast MIRM's revenue for 2026 to be $44,722,054,816, with the lowest MIRM revenue forecast at $42,570,850,931, and the highest MIRM revenue forecast at $46,566,129,381. On average, 14 Wall Street analysts forecast MIRM's revenue for 2027 to be $53,991,776,117, with the lowest MIRM revenue forecast at $45,331,118,880, and the highest MIRM revenue forecast at $61,129,123,870.
In 2028, MIRM is forecast to generate $70,451,440,255 in revenue, with the lowest revenue forecast at $60,096,701,843 and the highest revenue forecast at $84,606,660,509.